Modi Urges Indian Pharma Firms to Aim for Top Five Global Ranking

Prime Minister Narendra Modi yesterday called for Indian pharmaceutical companies to ascend to the ranks of the world’s top five, emphasizing the need to build on the sector’s existing strengths to achieve global leadership. Speaking during an event in New Delhi, Modi highlighted the industry’s potential to drive innovation and accessibility in healthcare while reinforcing India’s role as a key player in the global pharmaceutical landscape (PIB).

The Prime Minister’s remarks underscored the government’s push to scale up domestic production, reduce dependency on imports, and leverage India’s cost-effective manufacturing capabilities. He noted recent initiatives aimed at fostering research and development, streamlining regulatory frameworks, and encouraging collaborations between industry and academia. Modi also acknowledged the sector’s resilience, particularly its role in supplying affordable medicines worldwide during the COVID-19 pandemic, which bolstered India’s reputation as a reliable supplier (PIB).

India currently ranks among the world’s top ten pharmaceutical markets, with a significant share of generic drug exports. However, achieving a top-five position would require addressing challenges such as intellectual property hurdles, increasing investments in cutting-edge technologies, and strengthening quality control standards to meet stringent global requirements. Industry experts have cited the need for sustained policy support and infrastructure development to compete with leaders like the United States, China, and Japan (PIB).

While Modi’s call sets an ambitious target, the timeline and specific strategies for reaching the top five remain unclear. The government has yet to outline concrete milestones or funding allocations, leaving stakeholders to await further details on how this vision will translate into actionable plans.